- Home
- AVBP vs TSHA Comparison
AVBP vs TSHA Comparison
Compare AVBP & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVBP
- TSHA
- Stock Information
- Founded
- AVBP 2021
- TSHA 2019
- Country
- AVBP United States
- TSHA United States
- Employees
- AVBP N/A
- TSHA N/A
- Industry
- AVBP
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- AVBP
- TSHA Health Care
- Exchange
- AVBP NYSE
- TSHA Nasdaq
- Market Cap
- AVBP 862.8M
- TSHA 728.4M
- IPO Year
- AVBP 2024
- TSHA 2020
- Fundamental
- Price
- AVBP $21.63
- TSHA $2.68
- Analyst Decision
- AVBP Strong Buy
- TSHA Strong Buy
- Analyst Count
- AVBP 8
- TSHA 6
- Target Price
- AVBP $38.38
- TSHA $8.17
- AVG Volume (30 Days)
- AVBP 484.4K
- TSHA 2.8M
- Earning Date
- AVBP 08-13-2025
- TSHA 08-11-2025
- Dividend Yield
- AVBP N/A
- TSHA N/A
- EPS Growth
- AVBP N/A
- TSHA N/A
- EPS
- AVBP N/A
- TSHA N/A
- Revenue
- AVBP N/A
- TSHA $7,224,000.00
- Revenue This Year
- AVBP $85.82
- TSHA N/A
- Revenue Next Year
- AVBP N/A
- TSHA N/A
- P/E Ratio
- AVBP N/A
- TSHA N/A
- Revenue Growth
- AVBP N/A
- TSHA N/A
- 52 Week Low
- AVBP $15.47
- TSHA $1.05
- 52 Week High
- AVBP $36.37
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- AVBP 47.74
- TSHA 59.68
- Support Level
- AVBP $19.71
- TSHA $2.33
- Resistance Level
- AVBP $22.32
- TSHA $2.51
- Average True Range (ATR)
- AVBP 1.32
- TSHA 0.14
- MACD
- AVBP -0.20
- TSHA 0.02
- Stochastic Oscillator
- AVBP 31.89
- TSHA 90.43
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.